skip to Main Content

Pancreatic Cancer Organoids May Be a Platform to Study Response to Immunotherapies

Newsfeed image, light gray text on dark gray background
Organoids propagated from pancreatic cancer cells may provide a platform to study response to immune checkpoint inhibitors, according to a study presented at the AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachuseetts.

Though immune checkpoint inhibitors have been successful in many solid tumors, results with pancreatic ductal adenocarcinoma (PDAC) have been disappointing. The purpose of this study was to use PDAC organoids, which are microtumors created from cells harvested from patients during resection, to evaluate their immune reactivity and response to immune checkpoint inhibitors. Read more . . . 

Back To Top